Adial Pharmaceuticals shares are trading higher after the company announced that the first patient has been does in its pharmacokinetics study of AD04 for Alcohol Use Disorder.
Portfolio Pulse from Benzinga Newsdesk
Adial Pharmaceuticals shares are trading higher after the company announced that the first patient has been dosed in its pharmacokinetics study of AD04 for Alcohol Use Disorder.
June 05, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adial Pharmaceuticals shares are trading higher following the announcement that the first patient has been dosed in its pharmacokinetics study of AD04 for Alcohol Use Disorder.
The dosing of the first patient in a pharmacokinetics study is a significant milestone for Adial Pharmaceuticals, indicating progress in the development of AD04 for Alcohol Use Disorder. This positive development is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100